RET and neoplasm: Importantly, two patients (2.4%) were treated with sorafenib, lenvatinib, and then NTRK inhibitors, and one patient (1.2%) was treated with lenvatinib as first-line therapy and then with a RET inhibitor, according to the molecular profile of the patient’s tumor.